The effects of ZD1839 (Iressa), a highly selective EGFR tyrosine kinase inhibitor, as a radiosensitiser in bile duct carcinoma cell lines

International Journal of Oncology

Volumn 28, Issue 4, 2006, Pages 915-921

  Miyata, Hideki ^a   Sasaki, Tamito ^a   Kuwahara, Kenichi ^a   Serikawa, Masahiro ^a   Chayama, Kazuaki ^a  

^a HIROSHIMA UNIVERSITY   (Japan)

Author keywords

AKT; Bile duct carcinoma; EGFR; Radiation; ZD1839

Indexed keywords

1,3 BUTADIENE DERIVATIVE; 1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; 2 MORPHOLINO 8 PHENYLCHROMONE; 2-(4-MORPHOLINYL)-8-PHENYL-4H-1-BENZOPYRAN-4-ONE; 4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; ANTHRA(1,9 CD)PYRAZOL 6(2H) ONE; ANTHRA(1,9-CD)PYRAZOL-6(2H)-ONE; ANTHRACENE DERIVATIVE; CHROMONE DERIVATIVE; ENZYME INHIBITOR; EPIDERMAL GROWTH FACTOR RECEPTOR; GEFITINIB; IMIDAZOLE DERIVATIVE; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; MORPHOLINE DERIVATIVE; NITRILE; ONCOPROTEIN; PROTEIN KINASE INHIBITOR; PYRIDINE DERIVATIVE; QUINAZOLINE DERIVATIVE; RADIOSENSITIZING AGENT; STRESS ACTIVATED PROTEIN KINASE;

ARTICLE; BILE DUCT TUMOR; CELL CLONE; CELL PROLIFERATION; CELL SURVIVAL; CYTOLOGY; DOSE RESPONSE; DRUG ANTAGONISM; DRUG EFFECT; ENZYME ACTIVATION; HUMAN; METABOLISM; PATHOLOGY; PHOSPHORYLATION; RADIATION EXPOSURE; TUMOR CELL LINE;

ANTHRACENES; BILE DUCT NEOPLASMS; BUTADIENES; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CHROMONES; CLONE CELLS; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME ACTIVATION; ENZYME INHIBITORS; HUMANS; IMIDAZOLES; JNK MITOGEN-ACTIVATED PROTEIN KINASES; MITOGEN-ACTIVATED PROTEIN KINASES; MORPHOLINES; NITRILES; ONCOGENE PROTEIN V-AKT; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; PYRIDINES; QUINAZOLINES; RADIATION-SENSITIZING AGENTS; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 33744729984     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.28.4.915     Document Type: Article

References (45)

1. 192Ir intraluminal brachytherapy in treatment of malignant obstructive jaundice. World J Gastroenterol 10: 3506-3510, 2004.
2. Klapper LN, Glathe S, Vaisman N, Hynes NE, Andrews GC, Sela M and Yarden Y: The ErbB-2/HER2 oncoprotein of human carcinoma may function solely as a shared coreceptor for multiple stroma-drived growth factors. Proc Natl Acad Sci USA 96: 4995-5000, 1999.
3. Suzuki M, Umino T, Katayo T, Takeuchi H, Oikawa M, Ono K, Hayashi Y, Satou T and Matsuno M: Biliary metalic stenting and chemoradiation therapy for unresectable bile duct carcinoma. J Biliary Tract Pancreas 22: 255-259, 2001.
4. Wilks AF: Protein tyrosine kinase growth factor receptors and their ligands in development, differentiation, and cancer. Adv Cancer Res 60: 43-73, 1993.
5. Woodburn JR: The epidermal growth factor receptor and its inhibition cancer therapy. Pharmacol Ther 82: 241-250, 1999.
6. Ito Y, Takeda T, Sasaki T, Yamada T, Ishiguro S, Imaoka S, Tsujimoto M, Sakon M, Higashiyama S, Monden M and Matsuura N: Expression and clinical significance of erbB family in intrahepatic cholangiocellular carcinoma. Pathol Res Pract 197: 95-100, 2001. (Pubitemid 32194502)
7. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A and McGuire WL: Human breast cancer: correlation of relapse and survival with amplification of the HER2/neu oncogene. Science 235: 177-182, 1987.
8. Suzuki H, Isaji S, Pairojkul C and Uttaravichien T: Comoparative clinicopathological study of resected intrahepatic cholangiocarcinoma in northeast Thailand and Japan. J Hepatobiliary Pancreat Surg 7: 206-211, 2000.
9. Chow NH, Huang SM, Chan SH, Mo LR, Hwang MH and Su WC: Significance of c-erbB-2 expression in normal and neoplastic epithelium of biliary tract. Anticancer Res 15: 1055-1060, 1995.
10. Endo K, Yoon BI, Pairojkul C, Demetris AJ and Sirica AE: ERBB-2 overexpression and cyclooxygenase-2 up-regulation in human chorangiocarcinoma and risk condition. Hepatology 36: 439-450, 2002.
11. Han J, Lee JD, Bibbs L and Ulevitch RJ: A MAP kinase targeted by endotoxin and hyperosmolarity in mammalian cells. Science 265: 808-811, 1994.
12. Lee JC, Laydon JT, McDonnnell PC, Gallagher TF, Kumar S, Green D, McNulty D, Blumenthal MJ, Heys JR and Landvatter SW: A protein kinase involved in the regulation of inflammatory cytokinase biosynthesis. Nature 372: 739-746, 1994.
13. Dent P, Reardon DB, Park JS, Bowers G, Logsdon C, Valerie K and Schmidt-Ullrich R: Radiation-induced release of transformating growth factor alpha activates the epidermal growth factor receptor and mitogen-activated protein kinase pathway in carcinoma cells, leading to increased proliferation and protection from radiation-induced cell death. Mol Biol Cell 10: 2493-2506, 1999.
14. Hagan M, Wang L, Hanley JR, Park JS and Dent P: Ionizing radiation-induced mitogen-activated protein (MAP) kinase activation in DU145 prostate carcinoma cells: MAP kinase inhibition enhances radiation-induced cell killing and G2/M-phase arrest. Radiat Res 153: 371-383, 2000.
15. Bulavin DV, Amundson SA and Fornace AJ: p38 and Chk1 kinases: different conductors for the G(2)/M checkpoint symphony. Curr Opin Genet Dev 12: 92-97, 2002.
16. Gupta AK, Bakanauskas VJ, Cerniglia GJ, Cheng Y, Bernhard EJ, Muschel RJ and McKenna WG: RAS-mediated radiation resistance is not linked to MAP kinase activation in two bladder carcinoma cell lines. Radiat Res 154: 64-72, 2000.
17. Claus B, Paul K, Justine R, Heidrun F, Michael B and Wilfried B: MEK1 and ERK1/2 kinases as targets for the modulation of radiation responses. Anticancer Res 20: 3243-3250, 2000.
18. Grana TM, Rusyn EV, Zhou H, Sartor CI and Cox AD: Ras mediates radiaoresistance through both phosphatidylinositol 3-kinase-dependent and Raf-dependent but mitogen-activated protein kinase/extracellular signal-regulated kinase kinase-independent signaling pathways. Cancer Res 62: 4142-4150, 2002.
19. Zhou BP, Liao Y, Xia W, Spohn B, Lee MH and Hung MC: Cytoplasmic localization of p21Cip1/WAF1 by Akt-induced phosphorylation in HER2/neu-overexpressing cells. Nat Cell Biol 3: 245-252, 2001.
20. Rossig L, Jadidi AS, Urbich C, Badorff C, Zeiher AM and Dimmeler S: Akt-dependent phosphorylation of p21Cip1 regulates PCNA binding and proliferation of endothelial cells. Mol Cell Biol 21: 5644-5657, 2001.
21. Kim D, Kim S, Koh H, Yoon SO, Chung AS, Cho KS and Chung J: Akt/PKB promotes cancer cell invasion via increased motility and metalloprotease production. FASEB J 15: 1953-1962, 2001.
22. Gupta AK, Bakanauskas VJ, Cerniglia GC, Cheng Y, Bernhard EJ, Muschel RJ and McKenna WG: The Ras radiation resistance pathway. Cancer Res 61: 4278-4282, 2001.
23. Gupta AK, Cerniglia GJ, Mick R, Ahmed MS, Bakanauskas VJ, Muschel RJ and McKenna WG: Radiation sensitization of human cancer cells in vivo by inhibiting the activity of PI3K using LY294002. Int J Radiat Oncol Biol Phys 56: 846-853, 2003.
24. Edwards E, Geng L, Tan J, Onishko H, Donnelly E and Hallahan DE: Phosphatidylinositol 3-kinase/Akt signaling in the response of vascular endothelium to ionizing radiation. Cancer Res 62: 4671-4677, 2002.
25. Tanno S, Yanagawa N, Habiro A, Koizumi K, Nakano Y, Osanai M, Mizukami Y, Okumura T, Testa JR and Kohgo Y: Serine/threonine kinase AKT is frequently activated in human bile duct cancer and is association with increased radioresistance. Cancer Res 64: 3486-3490, 2004.
26. Moasser MM, Basso A, Averbunch SD and Rosen N: The tyrosine kinase inhibitor ZD1839 ('Iressa') inhibits HER2-driven signaling and suppresses the growth of HER2-overexpressing tumor cells. Cancer Res 61: 7184-7188, 2001.
27. Maddineni SB, Sangar VK, Hendry JH, Margison GP and Clake NW: Differential radiosensitisation by ZD1839 (Iressa), a highly selective epidermal growth factor receptor tyrosine kinase inhibitor in two related bladder cancer cell lines. Br J Cancer 92: 125-130, 2005.
28. Gupta AK, McKenna WG, Weber CN, Feldman MD, Goldmith JD, Mick R, Machtay M, Rosenthal DI, Bakanauskas VJ, Cerniglia GJ, Bernhard EJ, Weber RS and Muschel RJ: Local recurrence in head and neck cancer: relationship to radiation resistance and signal transduction. Clin Cancer Res 8: 885-892, 2002.
29. Stea B, Falsey R, Kislin K, Patel J, Glanzberg H, Carey S, Ambrad AA, Meuillet EJ and Martinez JD: Time and dose-dependent radiosensitization of the glioblastoma multiple U251 cells by the EGF receptor tyrosine kinase inhibitor ZD1839 ('Iressa'). Cancer Lett 202: 43-51, 2003.
30. Williams KJ, Telfer BA, Stratford IJ and Wedge SR: ZD1839 ('Iressa'), a specific oral epidermal growth factor receptor-tyrosine kinase inhibitor, potentiates radiotherapy in a human colorectal cancer xenograft model. Br J Cancer 86: 1157-1161, 2002.
31. Huang SM, Li J, Armstrong EA and Harari PM: Modulation of radiation response and tumor-induced angiogenesis after epidermal growth factor receptor inhibition by ZD1839 (Iressa). Cancer Res 62: 4300-4306, 2002.
32. Solomon B, Hagekyriakou J, Trivett MK, Stacker SA, McArthur GA and Cullinane C: EGFR blockade with ZD1839 ('Iressa') potentiates the antitumor effects of single and multiple fractions of ionizing radiation in human A431 squamous cell carcinoma. Int J Oncol Biol Phys 55: 713-723, 2003.
33. Gee JM and Nicholson RI: Expanding the therapeutic repertoire of epidermal growth factor receptor blockade: radiosensitization. Breast Cancer Res 5: 126-129, 2003.
34. Liang K, Jin W, Knuefermann C, Schmidt M, Mills GB, Ang KK, Milas L and Fan Z: Targeting the phosphatidylinositol 3-kinase/Akt pathway for enhancing breast cancer cells to radiotherapy. Mol Cancer Ther 2: 353-360, 2003.
35. Akimoto T, Hunter NR, Buchmiller L, Mason K, Ang KK and Milas L: Inverse relationship between epidermal growth factor receptor expression and radiocurability of murine carcinomas. Clin Cancer Res 5: 2884-2890, 1999.
36. Hosoi Y: Radiation-induced signal transduction pathways: DNA double-strand break repair and radiation-induced activation of EGFR. Jpn J Cancer Clin 50: 1055-1060, 2004.
37. Alessi DR, Andjelkovic M, Caudwell B, Cron P, Morrice N, Cohen P and Hemmings BA: Mechanism of activation of protein kinase B by insulin and IGF-1. EMBO J 15: 6541-6551, 1996.
38. Alessi DR, Deak M, Casamayor A, Caudwell FB, Morrice N, Norman DG, Gaffney P, Reese CB, MacDougall CN, Harbison D, Ashworth A and Bownes M: 3-Phosphoinositide-dependent protein kinase-1 (PDK1): structural and functional homology with the Drosophila DSTPK61 kinase. Curr Biol 7: 776-789, 1997.
39. Cantley LC and Neel BG: New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway. Proc Natl Acad Sci USA 96: 4240-4245, 1999.
40. Testa JR and Bellacosa A: AKT plays a central role in tumorigenesis. Proc Natl Acad Sci USA 98: 10983-10985, 2001.
41. Franke TF, Kaplan DR and Cantley LC: PI3K: downstream AKTion blocks apoptosis. Cell 88: 435-437, 1997.
42. Downward J: Mechanisms and consequences of activation of protein kinase B/Akt. Curr Opin Cell Biol 10: 262-267, 1998.
43. Moulder SL, Yakes FM, Muthuswamy SK, Bianco R, Simpson JF and Arteaga CL: Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo. Cancer Res 61: 8887-8895, 2001. (Pubitemid 34013905)
44. Anido J, Matar P, Albanell J, Guzman M, Rojo F, Arrbas J, Averbuch S and Baselga J: ZD1839, a specific epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, induces the formation of inactive EGFR/HER2 and EGFR/HER3 heterodimers and prevents heregulin signaling in HER2-overexpressing breast cancer cells. Clin Cancer Res 9: 1274-1283, 2003.
45. Olayioye MA, Neve RM, Lane HA and Hynes NE: The ErbB signaling network: receptor heterodimerization in development and cancer. EMBO J 19: 3159-3167, 2000.